Compare · BDMD vs DXCM
BDMD vs DXCM
Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDMD and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 528.6x BDMD ($53.2M).
- Over the past year, BDMD is down 72.4% and DXCM is down 10.1% - DXCM leads by 62.3 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 2 for BDMD).
- DXCM has more recent analyst coverage (25 ratings vs 0 for BDMD).
- Company
- Baird Medical Investment Holdings Ltd
- DexCom Inc.
- Price
- $1.31+3.56%
- $76.97+5.67%
- Market cap
- $53.2M
- $28.11B
- 1M return
- -29.76%
- +26.33%
- 1Y return
- -72.42%
- -10.12%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 2
- 26
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BDMD
- SEC Form POS AM filed by Baird Medical Investment Holdings Ltd
- SEC Form F-3 filed by Baird Medical Investment Holdings Ltd
- SEC Form SCHEDULE 13G filed by Baird Medical Investment Holdings Ltd
- Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update
- SEC Form 20-F filed by Baird Medical Investment Holdings Ltd
- SEC Form 3 filed by new insider Xu Lijian
- SEC Form 3 filed by new insider Qiu Quan
- SEC Form 3 filed by new insider Lu Rongjian
- SEC Form 3 filed by new insider Bilciu-Wolfson Gabrielle
- SEC Form 3 filed by new insider Li Jie Clara
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)